Search

Objective To investigate the clinical effect of repetitive transcranial magnetic stimulation (rTMS) therapy on Parkinson's disease (PD) using Meta - analysis. Methods Taking transcranial magnetic stimulation or TMS, Parkinson's disease or PD and randomized controlled trial as retrival words, search related articles during 1999 to 2013 from databases such as PubMed, EMBASE, Ovid MEDLINE, VIP, Wanfang and China National Knowledge Intrastructure (CNKI). Finally 16 articles (4 in Chinese and 12 in English) were included for Meta-analysis according to high-frequency stimulation (HFS > 1 Hz) and low-frequency stimulation (LFS ≤ 1 Hz) respectively. Results A total pf 455 PD patients were enrolled and divided into TMS group (N = 236) and control group (N = 219). After HFS and LFS therapies, the Unified Parkinson's Disease Rating Scale (UPDRS) score in TMS group was significantly different from control group (WMD = -5.010, 95%C1: -7.370--2.650, P = 0.000; WMD = -6.140, 95%C1: - 8.750-- 3.530, P = 0.000). After HFS therapy, the UPDRS H motor (WMD = -4.380, 95%C1: - 8.260-- 0.500; P = 0.003) and activities of daily living (ADL) scores (WMD = -3.740, 95%C1: -4.660-2.820; P = 0.000) in TMS group were significantly different from that in control group. There were no significant differences in UPDRS H motor score with LFS therapy (WMD = -2.160, 95%C1: -5.010-0.690; P = 0.370) and the Mini-Mental State Examination (MMSE) score with HFS therapy between 2 groups (WMD = 0.260, 95%C1: -0.660-1.180; P = 0.580). Conclusions Repetitive transcranial magnetic stimulation therapy can ameliorate partial symptoms of Parkinson's disease for enhancing the quality of life, however, the improvement for mental disability was not found. [ABSTRACT FROM AUTHOR]

In order to explore the distribution frequency of endothelial protein C receptor (EPCR) gene A6936G variant and to study the correlation between this mutation and cerebral infarction in Chinese Han population of Hubei province district. The genotype and allele frequencies of EPCR A6936G were identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) in 380 cerebral infarction patients and 380 healthy Chinese Han persons. The results indicated that the frequencies of A/A, A/G and G/G genotypes in cerebral infarction group were 77.1%, 22.1% and 0.8% respectively. While the frequencies of A/A and A/G genotypes in control group were 88.2% and 11.8%, and without G/G genotype. It is concluded that A6936G polymorphism of EPCR can be detected in Chinese Han population of Hubei province district, which may be correlated with the increasing risk of thrombosis in cerebral infarction patients.

Objective: To investigate the clinical significance of D-dimer detection in the diagnosis and treatment of thrombotic diseases., Methods: Peripheral blood samples were collected from 156 patients with acute cerebral infarction (ACI), 38 patients with deep venous thrombosis (DVT), and 148 patients with acute myocardial infarction (AMI), all under relevant treatment, and 170 healthy examinees. The level of plasma D-dimer was detected by ELISA before and after the treatment., Results: The positive rates of plasma D-dimer of the ACI, DVT, and AMI patients before treatment were 59.3%, 100.0%, and 61.7% respectively, all significantly higher than that of the health examinees (4.3%, all P < 0.01). And the positive rates of plasma D-dimer decreased rapidly after treatment in the patients of these 3 groups who responded magnificently to thrombolysis treatment (all P < 0.01)., Conclusion: Increased in most thrombotic patients, the plasma D-dimer level helps diagnose thrombotic diseases early and reflect the efficacy of thrombolysis treatment.

To investigate the interrelationship among morphology, immunology and clinical features in adult acute myeloid leukemia cases with 11q23 chromosome abnormalities, 210 newly diagnosed AML patients were retrospectively analyzed by cell morphology, immunophenotyping, G-banding or R-bamding analysis and clinical features. The results showed that 13 cases were found with 11q23 rearrangements or deletion (the incidence rate was 6.19%.), totally 84.6% showed the involvement with the monocytic lineage. Immunophenotyping tests indicated that AML cases with 11q23 abnormalities usually expressed the marker molecules of hematopoietic stem or progenitor cells, monocytic lineage cells, such as CD34, CD117, CD14, CD15 and CD11b. The complete remission rate of the cases with 11q23 abnormalities was comparable to that of the cases with normal karyotype (P = 0.075), but the median disease-free survival in the former was significantly lower than that in the latter (P < 0.001). It is concluded that the category AML with 11q23 abnormalities accounts for 6.19% of all the newly diagnosed AML cases, that seems to be closely associated with monocytic differentiation blocking with a dismal prognosis.